JPM Movers: ImmunityBio Rises to the Top
ImmunityBio announced a first‑in‑human readout of its off‑the‑shelf CD19 t‑haNK CAR‑NK therapy combined with rituximab, delivering a durable 15‑month complete response in four Waldenstrom lymphoma patients. The data propelled the stock to $5.52, up 137% from the prior week and added roughly $3.8 billion to market value. The company also reported strong enrollment for its IL‑15 agonist Anktiva trial in BCG‑naive non‑muscle‑invasive bladder cancer and aims to submit a BLA by year‑end. These milestones positioned ImmunityBio at the top of the J.P. Morgan Healthcare Conference movers list.
Stem Cell Gym Boosts Human Heart Cell Maturation
A new micro‑engineered platform dubbed the Stem Cell Gym has been shown to accelerate the maturation of human induced pluripotent stem cell‑derived cardiomyocytes. Researchers reported a 30‑40% increase in electrophysiological and contractile markers compared with conventional culture methods. The system...
Mitochondrial Transfer: Dual Impact on Health and Disease
Mitochondrial transfer, the movement of energy‑producing organelles between cells, is gaining prominence as a dual‑edged biological process. Healthy mitochondria can rescue stressed or damaged cells, offering therapeutic promise for neurodegenerative and cardiac diseases. Conversely, tumor cells may hijack this mechanism...
Korea’s Ildong Promotes Chae Joon Lee to Co-CEO
Ildong Pharmaceutical promoted Chae Joon Lee from COO to co‑CEO while retaining his president role, and he will continue overseeing affiliates such as Yunovia, ILeadBMS, and Idience. The move signals a leadership reshuffle aimed at integrating operational expertise with strategic...
New Genetic Insights Into Strobilanthes Cusia Cultivation
Researchers have sequenced the genome of Strobilanthes cusia and identified key genes governing indigo pigment production and stress tolerance. The study reveals specific transcription factors that boost alkaloid biosynthesis and pinpoint markers for high‑yield cultivars. Field trials using marker‑assisted selection...
Agomab and SpyGlass File for IPOs as Investor Enthusiasm Builds After JPM
SpyGlass Pharma and Agomab Therapeutics announced filings for initial public offerings on Friday, signaling a new wave of biotech listings. Both companies aim to capitalize on heightened investor enthusiasm sparked by JPMorgan's recent focus on life‑science investments. SpyGlass plans to...
More Cash Flows Into Biotechs During Conference Week: Finance Report
During the J.P. Morgan Healthcare Conference, biotech companies attracted roughly $950 million in new capital, spread across 19 mostly private firms. The influx followed an early‑2026 surge of venture deals that pushed total private biotech funding to about $3 billion. Most of...
AbbVie, Genmab Say Epkinly Didn't Prolong Overall Survival in Lymphoma Study
AbbVie and Genmab announced that their antibody‑drug conjugate Epkinly failed to extend overall survival in a Phase 3 trial for diffuse large B‑cell lymphoma (DLBCL). The study, which compared Epkinly plus standard chemotherapy against chemotherapy alone, showed no statistically significant OS...
Antioxidant Effects of Decolorized Rosemary in Pork
Researchers evaluated decolorized rosemary extract as a natural antioxidant for pork, demonstrating a 30% reduction in lipid oxidation and extending refrigerated shelf life by up to five days. The decolorization process removed the herb’s green color and strong flavor, preserving...
Drugmakers without MFN Pacts Are Bracing to Make One
Last year President Donald Trump urged almost all U.S. drugmakers to slash prices, but only 17 companies complied with a direct demand. The majority of manufacturers resisted, avoiding formal most‑favored‑nation (MFN) pricing agreements. Industry analysts now warn that, facing renewed...
Tiny Nanocourier that Delivers Molecular Packages to Cell Surface Unveiled
An international team led by Pompeu Fabra University scientists visualized the nanomachine that drives constitutive exocytosis, naming it ExHOS – a flexible ring formed by seven exocyst protein assemblies. Using combined advanced light, electron microscopy and AI‑driven image analysis, they...
Makary Talks FDA's Plans to Combat China's Biotech Growth
FDA Commissioner Marty Makary announced that the agency is overhauling its Phase 1 clinical‑trial framework to address the rapid influx of Chinese biotech firms into the U.S. market. The revision will tighten data‑integrity standards, boost early‑phase safety monitoring, and create clearer...
The Impact of Patient-Centric Formulations on Service Providers
Patient‑centric drug development is reshaping the pharmaceutical landscape, prompting sponsors to turn to CDMOs for specialized formulation services. Advanced modalities such as peptides and RNA therapies have heightened formulation complexity, driving a surge in outsourcing to CDMOs with AI‑enabled platforms...
Enhancing Nursing Students’ Genetics Experience Through Leadership
A new initiative at several nursing schools uses leadership-driven curricula to deepen genetics education for nursing students. Faculty mentors guide students through hands‑on genomic case studies, simulation labs, and interdisciplinary projects. Early assessments show a 22% rise in genetics competency...
MCM8 Accelerates Colorectal Cancer by Inhibiting Ubiquitination
A recent study reveals that the DNA helicase MCM8 is markedly overexpressed in colorectal cancer and drives tumor progression by blocking ubiquitination pathways. By preventing the degradation of oncogenic substrates, MCM8 stabilizes proteins that promote cell proliferation and metastasis. The...
PharmTech Weekly News Roundup – Week of January 12, 2026
The PharmTech Weekly roundup underscores a rapid shift toward agentic AI, sustainability, and resilient supply chains across drug development. The FDA and EMA released ten guiding principles for ethical AI use, while companies like Dycem, Jubilant Biosys, and SÜDPACK highlighted...
Scientists Transform Enigmatic Cell Structures Into Devices for Recording RNA Activity
Researchers have engineered the naturally occurring vault particle into a synthetic "TimeVault" that sequesters mRNA inside the ribonucleoprotein shell, protecting it from degradation for more than a week. By fusing a major‑vault‑protein binding domain with an mRNA‑binding motif, the system...
New SLAC Method Guides Better Cell Slice Preparation for Cryo-ET Imaging
SLAC National Accelerator Laboratory researchers have introduced a tri‑coincident system that synchronizes a scanning electron microscope, an ion‑beam mill, and an optical microscope to guide cryogenic electron tomography (cryo‑ET) sample preparation. By exploiting interference patterns in fluorescent light emitted from...
Vedanta ‘Significantly’ Reduces Staff, Focuses on Phase III Study of C. Diff Drug
Vedanta Biosciences announced a major headcount reduction, cutting roughly half of its workforce to preserve cash for a Phase III trial of its oral C. difficile candidate VE303. The layoffs follow earlier cuts after a failed Phase II study of VE202 and reflect...
Microglial FcγR Drives Dopaminergic Neuron Loss
A new study reveals that microglial Fcγ receptors (FcγR) actively drive the loss of dopaminergic neurons, a hallmark of Parkinson's disease. Researchers demonstrated that FcγR activation triggers inflammatory cascades that exacerbate neuronal death in both mouse models and human post‑mortem...
ImmunityBio's Cell Therapy Posts Encouraging Early Data in Rare Blood Cancer
ImmunityBio reported encouraging early data from its off‑the‑shelf cell‑therapy platform in a Phase 1 trial (QUILT) targeting a rare form of lymphoma. The small study demonstrated a favorable safety profile and preliminary efficacy signals, including objective responses in several patients. The...
Regulate DNA Fragments to Bypass Synthesis Screening
A proposed regulatory framework would allow short synthetic DNA fragments to bypass mandatory synthesis screening, aiming to streamline research and reduce costs. The draft sets a length threshold—typically 200 base pairs—and requires labs to register exempted fragments with a central...
Medications for Opioid Use Disorder: Overcoming Integration Barriers
Researchers Desai et al. identify persistent barriers that prevent medication‑assisted treatment (MAT) for opioid use disorder from being fully integrated into specialty programs. Stigma toward patients and providers, restrictive regulations, and insufficient clinician training limit the use of proven drugs such...
UC San Diego Launches ARPA-H Project to 3D Bioprint Patient-Specific Human Livers
UC San Diego, backed by a $25.8 million ARPA‑H grant, is developing a 3‑D bioprinting platform to create patient‑specific, functional human livers. The multidisciplinary team combines rapid light‑based printing with AI‑driven vascular design to fabricate complex, multi‑cellular tissue in seconds. Partnering...
JPM26: Protagonist Has a $400M Decision To Make. It’s a No-Brainer
Protagonist Therapeutics faces a pivotal choice on its rusfertide partnership with Takeda. The company is leaning toward opting out of the 50‑50 co‑development deal, which would trigger a $400 million opt‑out payment and tiered royalties up to 29% on sales exceeding...
Ensuring the Supply Chain Through Purchasing Controls
Establishing a secure supply chain now starts with early, cross‑functional purchasing controls. Development, quality, and procurement teams must collaborate to define requirements, qualify suppliers, and create quality agreements before scale‑up. The Parenteral Drug Association’s upcoming ANSI/PDA Standard 001‑2020 formalizes these expectations...
SÜDPACK Medica to Unveil Next-Generation Sustainable Packaging and Streamlined Services at Pharmapack Europe 2026
At Pharmapack Europe 2026, SÜDPACK Medica introduced its next‑generation PharmaGuard blister line, a mono‑material polypropylene solution that replaces multi‑layer composites with a recyclable, phthalate‑free film, now available in an opaque white version for better dosage readability. The company also launched...
#JPM26: Sandoz CEO on Ozempic Generic Launch Plans for 2026
Sandoz, Novartis' generics arm, announced plans to launch a generic version of Ozempic (semaglutide) in 2026. The move aligns with the anticipated expiration of Novo Nordisk's patents on the GLP‑1 drug, opening the U.S. and European markets to lower‑priced alternatives....
Wegovy Pill Shows Strong Early Uptake, as Rival Looms
Novo Nordisk's oral Wegovy pill recorded 3,071 prescriptions within its first four days on the U.S. market, a figure that excludes sales through its NovoCare direct‑to‑consumer channel. The launch arrives as Eli Lilly awaits an FDA decision on its own oral...
JPM 2026: What’s the Outlook Like This Year?
The J.P. Morgan Healthcare Summit in San Francisco highlighted a surge in radiopharmaceutical development, positioning precision radiation therapy as a key growth area in oncology. AI‑driven molecular profiling is accelerating biomarker discovery and drug design, while the GLP‑1 market expands with...
Sanofi Linked to Takeover Bid for Ocular Therapeutix
Sanofi is reportedly preparing a renewed takeover bid for US‑based Ocular Therapeutix after its initial $16‑per‑share offer was rejected last summer. Ocular, valued at roughly $2.4 billion with shares trading around $11.28, is poised to file for approval of Axpaxli, a...
JPM26: Deal Hungry Novo Moves With ‘Intention’ To Put Metsera in the Rearview
Novo Nordisk is revamping its business‑development approach under new CEO Mike Maziar Doustdar, emphasizing intentional M&A and licensing to accelerate its obesity and diabetes pipeline. The company recently closed a $5.2 billion acquisition of Akero Therapeutics and secured a China partnership...
Komodo Health Appoints Amit Sangani to Chief Technology Officer
Komodo Health announced Amit Sangani as its new chief technology officer, tasked with steering the AI‑native Marmot platform. Sangani arrives after an 11‑year tenure at Meta, where he led large‑scale AI systems including PyTorch and Llama, and previously co‑founded MightyText....
Former Emergent CEO Hit With Insider Trading Lawsuit
The New York Attorney General sued former Emergent BioSolutions CEO Robert Kramer for alleged insider trading, claiming he sold stock based on nonpublic knowledge of vaccine contamination. Kramer reportedly profited over $10.1 million from trades executed between November 2020 and early 2021....
Writing the Code of Life: Synthetic Human Chromosomes on the Horizon
The Wellcome‑funded Synthetic Human Genome (SynHG) project has launched a £10 million, five‑year effort to develop scalable technologies for building synthetic human chromosomes. The consortium of five UK universities aims to create the first fully synthetic human genome, tackling challenges from...
Automated Twist Bioscience NGS Library Prep Workflows Enabled on SPT’s Firefly
SPT Labtech has launched validated automated workflows for Twist Bioscience’s next‑generation sequencing (NGS) library preparation kits on its firefly® liquid handling platform. The initial offering supports the FlexPrep™ UHT kit and integrates the Twist Enzymatic Fragmentation Kit 2.0, delivering higher‑throughput,...
JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
Korro Bio’s lead RNA‑editing candidate KRRO‑110 failed its Phase I/IIa trial for alpha‑1 antitrypsin deficiency, prompting an 80% stock plunge and a one‑third staff layoff. A root‑cause analysis revealed the lipid nanoparticle delivery vehicle achieved only about 25% of the...
European Regulators Recommended 38 Novel Drugs in 2025, 15 Fewer than the FDA
The European Medicines Agency (EMA) recommended 104 medicines for approval in 2025, marking the second‑highest total in the past 15 years. Of those, 38 are classified as novel drugs, a figure that trails the U.S. Food and Drug Administration (FDA)...
Ocugen Shares Fall, Despite Positive Eye Disorder Trial
Ocugen reported that its phase‑2 ArMaDa trial of the gene therapy OCU410 achieved a 46% reduction in geographic atrophy lesion growth for medium and high doses, with the medium dose showing a 54% reduction. The data also revealed a 60%...
Novo Nordisk, BioMarin Make AI Moves; Bristol Myers Welcomes Neurology Exec From Eisai
Novo Nordisk and BioMarin announced strategic partnerships to integrate artificial intelligence into their drug discovery pipelines, aiming to accelerate candidate identification and reduce development costs. Novo Nordisk highlighted a collaboration with a leading AI firm to model peptide therapeutics, while...
Autonomous AI Can Spot Cognitive Decline in Medical Notes
Researchers at Mass General Brigham unveiled an autonomous, agentic AI system that scans routine clinical notes to flag early cognitive impairment. The platform, built from five specialized LLM agents, demonstrated 98% specificity and 91% sensitivity in balanced testing, though real‑world...
EDETEK Launches “Ensemble” AI Managed Services
EDETEK Inc. unveiled Ensemble, an AI‑managed service that operationalizes validated, human‑supervised artificial intelligence across the clinical development lifecycle. The offering combines best‑fit large language and multimodal models, agentic automation, and domain experts to deliver production‑grade outputs such as SAP, SDTM,...
Immune-Regulating Lipid Signals May Provide a Path to Treat Chronic Inflammation
Scientists at University College London identified epoxy‑oxylipins as natural brakes that curb chronic inflammation by limiting intermediate monocyte expansion. In a human trial, the soluble epoxide hydrolase inhibitor GSK2256294 boosted epoxy‑oxylipin levels, accelerated pain resolution and lowered monocyte counts, though...
Psychiatric Nurses’ Views on AI in Care
A recent qualitative study of Chinese psychiatric nurses reveals a nuanced stance toward artificial intelligence in mental‑health care. Nurses largely view AI as a supportive tool that can automate routine tasks and enhance decision‑making, yet they voice strong concerns about...
Plant Discovery Could Lead to New Ways of Producing Medicines
Researchers at the University of York identified a bacterial‑like gene in the plant Flueggea suffruticosa that drives production of the potent alkaloid securinine, revealing that plants can co‑opt microbial enzymes for chemical defense. This discovery shows the gene family is...
Labiotech’s 15 Biopharma Companies to Watch in 2026
Labiotech‑EU hosted a special podcast where journalists Jules Adam, Roohi Peter and Willow Shah‑Neville each highlighted five biotech firms they expect to shape 2026, creating a curated list of 15 companies. The selections span gene‑therapy, immunology, neuroscience and platform technologies, featuring names such...
Patient Perspectives on Frailty Screening in Emergencies
A qualitative study published in BMC Geriatrics explores how emergency‑department patients experience frailty screening. Researchers interviewed older adults to capture feelings ranging from anxiety about being labeled frail to relief at receiving tailored care. The findings highlight how the hectic...
Revealing RNA Polymerase II Start Sites via csRNA-Seq
A new study introduces csRNA‑seq, a high‑resolution method that captures active RNA Polymerase II transcription start sites across the genome. The technique isolates short, capped RNAs, enabling precise mapping of promoter activity without requiring chromatin immunoprecipitation. Early validation in human...
Restoring FBP1 Boosts Erectile Function in Diabetic Mice
A recent pre‑clinical study demonstrated that restoring the enzyme fructose‑1,6‑bisphosphatase 1 (FBP1) in diabetic mice markedly improves erectile function. The researchers used a targeted gene‑therapy approach to re‑express FBP1 in penile tissue, which rescued nitric oxide signaling and vascular responsiveness. Treated...
Resolving DNA Origami Structural Integrity and Pharmacokinetics in Vivo
The study introduces PLASTIQ, a proximity‑ligation assay that quantifies intact DNA origami structures in vivo with single‑helix resolution. Using ligatable staple pairs, the method detects intact nanostructures from as little as 1 µl of blood, achieving a 0.01 fM detection limit. PLASTIQ...
